scholarly journals Investigator bias and the PACE trial

2017 ◽  
Vol 22 (9) ◽  
pp. 1123-1127 ◽  
Author(s):  
Steven Lubet
Keyword(s):  
2005 ◽  
Vol 35 (5) ◽  
pp. 1046-1066 ◽  
Author(s):  
Jaume Masip ◽  
Hernan Alonso ◽  
Eugenio Garrido ◽  
Concha Anton

1999 ◽  
Vol 84 (6) ◽  
pp. 940-951 ◽  
Author(s):  
Mark R. Phillips ◽  
Bradley D. McAuliff ◽  
Margaret Bull Kovera ◽  
Brian L. Cutler

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Luke Ternes ◽  
Ge Huang ◽  
Christian Lanciault ◽  
Guillaume Thibault ◽  
Rachelle Riggers ◽  
...  

AbstractMechanistic disease progression studies using animal models require objective and quantifiable assessment of tissue pathology. Currently quantification relies heavily on staining methods which can be expensive, labor/time-intensive, inconsistent across laboratories and batch, and produce uneven staining that is prone to misinterpretation and investigator bias. We developed an automated semantic segmentation tool utilizing deep learning for rapid and objective quantification of histologic features relying solely on hematoxylin and eosin stained pancreatic tissue sections. The tool segments normal acinar structures, the ductal phenotype of acinar-to-ductal metaplasia (ADM), and dysplasia with Dice coefficients of 0.79, 0.70, and 0.79, respectively. To deal with inaccurate pixelwise manual annotations, prediction accuracy was also evaluated against biological truth using immunostaining mean structural similarity indexes (SSIM) of 0.925 and 0.920 for amylase and pan-keratin respectively. Our tool’s disease area quantifications were correlated to the quantifications of immunostaining markers (DAPI, amylase, and cytokeratins; Spearman correlation score = 0.86, 0.97, and 0.92) in unseen dataset (n = 25). Moreover, our tool distinguishes ADM from dysplasia, which are not reliably distinguished with immunostaining, and demonstrates generalizability across murine cohorts with pancreatic disease. We quantified the changes in histologic feature abundance for murine cohorts with oncogenic Kras-driven disease, and the predictions fit biological expectations, showing stromal expansion, a reduction of normal acinar tissue, and an increase in both ADM and dysplasia as disease progresses. Our tool promises to accelerate and improve the quantification of pancreatic disease in animal studies and become a unifying quantification tool across laboratories.


2011 ◽  
Vol 35 (6) ◽  
pp. 452-465 ◽  
Author(s):  
Fadia M. Narchet ◽  
Christian A. Meissner ◽  
Melissa B. Russano

2000 ◽  
Vol 85 (2) ◽  
pp. 304-304
Author(s):  
Mark R. Phillips ◽  
Bradley D. McAuliff ◽  
Margaret Bull Kovera ◽  
Brian L. Cutler

2018 ◽  
Author(s):  
Felix J. Hartmann ◽  
Joel Babdor ◽  
Pier Federico Gherardini ◽  
El-Ad D. Amir ◽  
Kyle Jones ◽  
...  

SummaryThe success of immunotherapy has led to a myriad of new clinical trials. Connected to these trials are efforts to discover biomarkers providing mechanistic insight and predictive signatures for personalization. Still, the plethora of immune monitoring technologies can face investigator bias, missing unanticipated cellular responses in limited clinical material. We here present a mass cytometry workflow for standardized, systems-level biomarker discovery in immunotherapy trials. To broadly enumerate human immune cell identity and activity, we established and extensively assessed a reference panel of 33 antibodies to cover major cell subsets, simultaneously quantifying activation and immune checkpoint molecules in a single assay. The resulting assay enumerated ≥ 98% of peripheral immune cells with ≥ 4 positively identifying antigens. Robustness and reproducibility were demonstrated on multiple samples types, across research centers and by orthogonal measurements. Using automated analysis, we monitored complex immune dynamics, identifying signatures in bone-marrow transplantation associated graft-versus-host disease. This validated and available workflow ensures comprehensive immunophenotypic analysis, data comparability and will accelerate biomarker discovery in immunomodulatory therapeutics.


2002 ◽  
Vol 26 (5) ◽  
pp. 469-480 ◽  
Author(s):  
Christian A. Meissner ◽  
Saul M. Kassin
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document